Hospital Clínico Universitario de Valencia
Valencia, 46010, Spain
Location status: Recruiting
NCT Number: NCT07816562
This study aims to compare different ovulation triggering strategies in women with low ovarian reserve undergoing fresh in vitro fertilization (IVF) cycles.
Ovulation triggering is a key step in IVF treatment, as it determines final oocyte maturation prior to oocyte retrieval.
Participants are randomly assigned to one of three ovulation trigger approaches: human chorionic gonadotropin (hCG) alone, follitropin delta combined with hCG, or dual trigger using a gonadotropin-releasing hormone (GnRH) agonist plus hCG.
The primary objective is to evaluate wether adding follitropin delta at the time of triggering increases the number of matura oocytes obtained, without adversely affecting implantation rates. Pregnancy otucomes following fresh embryo transfer will also be assessed.
The results of this study may help optimize ovulation triggering strategies in women with low ovarian reserve undergoing IVF treatment.
Interested in participating?
Request Info18 year–42 year
Female
Interventional
Phase 3
Valencia, 46010, Spain
Location status: Recruiting
Final oocyte maturation is a critical step in assisted reproductive techniques (ART) and is largely determined by the ovulation triggering strategy. In women with low ovarian reserve, achieving an adequate number of mature oocytes remains a major challenge, even when established trigger protocols are used.
Dual trigger strategies combining hCG and a GnRH agonist are widely used in this population, based on evidence suggesting improved oocyte maturation. However, despite this approach, oocyte yield and maturity often remain suboptimal. The addition of exogenous follicle-stimulating hormone (FSH) activity at the time of ovulation triggering has been proposed as a potential strategy to further optimize final oocyte maturation.
Follitropin delta has a distinct pharmacokinetic profile and provides individualized FSH exposure based on ovarian reserve markers. Its use in combination with hCG at the time of triggering may enhance oocyte maturation without compromising endometrial receptivity.
This prospective, randomized study compares three ovulation triggering strategies in women with low ovarian reserve undergoing fresh IVF cycles: hCG alone, follitropin delta combined with hCG, and dual triggering using a GnRH agonist plus hCG. Participants are randomly assigned to one of the three groups.
The primary outcome is the number of mature oocytes (metaphase II, MII) obtained at oocyte retrieval. Secondary outcomes include the proportion of mature oocytes, biochemical pregnancy rate per embryo transfer, and ongoing pregnancy rate following fresh embryo transfer.
The study aims to generate evidence to optimize ovulation triggering strategies in women with low ovarian reserve.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Human chorionic gonadotropin (hCG) administered for final oocyte maturation and ovulation triggering.
Other names: hCG
Follitropin delta administered as part of the ovulation-triggering regimen for final oocyte maturation.
(hCG).
Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, administered as part of the ovulation-triggering regimen for final oocyte maturation.
Time frame: During the oocyte retrieval procedure
Number of metaphase II (MII) oocytes obtained at oocyte retrieval following ovulation triggering
Time frame: During the oocyte retrieval procedure
Percentage of metaphase II (MII) oocytes relative to the total number of oocytes retrieved.
Time frame: 10-14 days after embryo transfer
Positive beta-human chorionic gonadotropin (beta-hCG) test following fresh embryo transfer.
Time frame: 6-7 weeks of gestation
Presence of a viable intrauterine pregnancy confirmed by ultrasound.
Contact information is provided by the study sponsor or research team.
Fundación para la Investigación del Hospital Clínico de Valencia
Other
Ovulation Trigger Strategies in Women With Low Ovarian Reserve Undergoing Fresh In Vitro Fertilization Cycles: A Prospective Randomized Controlled Trial (TRIGGERBEST)
Acronym: TRIGGERBEST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06975683
Low Ovarian Reserve
Madrid, Spain
View Trial DetailsNCT07270081
Low Ovarian Reserve, Poor Response to Ovulation Induction
Alicante, Spain
View Trial DetailsNCT02696889
Adnexal Diseases, Amenorrhea
Chicago, Illinois, United States
View Trial DetailsNCT06645379
Adnexal Diseases, Endocrine System Diseases
Yiwu, Zhejiang, China
View Trial Details